Evidence map›Paper›PMID 21628524›Full record

ArticleInfection and immunity2011

CXCR6 is a marker for protective antigen-specific cells in the lungs after intranasal immunization against Mycobacterium tuberculosis.

Lian Ni Lee, Edward O Ronan, Catherine de Lara, Kees L M C Franken, Tom H M Ottenhoff, Elma Z Tchilian, Peter C L Beverley

Open access · greenAbstract read
In one paragraph

Article in Infection and immunity, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 57 citations in OpenAlex.

  1. Article
  2. Review
  3. Pan-cancer mapping of single CD8Cell reports. Medicine · 2024
    Article
  4. Innate acting memory Th1 cells modulate heterologous diseases.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  5. rs71327024 Associated with COVID-19 Hospitalization ReducesInternational journal of molecular sciences · 2023
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. CXCR6 deficiency impairs cancer vaccine efficacy and CD8Journal for immunotherapy of cancer · 2021
    Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Antigens ofFrontiers in immunology · 2020
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Lian Ni LeeNuffield Department of Medicine, University of Oxford, The Peter Medawar Building for Pathogen Research, South Parks Road, Oxford OX1 3SY, United Kingdom.
Edward O Ronan
Catherine de Lara
Kees L M C Franken
Tom H M Ottenhoff
Elma Z Tchilian
Peter C L Beverley
University of Oxford · GBLeiden University Medical Center · NLMedawar Building for Pathogen Research · GB

Funding

Medical Research Council G0701235Medical Research Council G1100085
6 · The paper itself

Abstract

Convincing correlates of protective immunity against tuberculosis have been elusive. In BALB/c mice, intranasal immunization with a replication-deficient recombinant adenovirus expressing Mycobacterium tuberculosis antigen 85A (adenovirus-85A) induces protective lower respiratory tract immunity against pulmonary challenge with Mycobacterium tuberculosis, while intradermal immunization with adenovirus-85A does not. Here we report that intranasal immunization with adenovirus-85A induces expression of the chemokine receptor CXCR6 on lung CD8 T lymphocytes, which is maintained for at least 3 months. CXCR6-positive antigen-specific T cell numbers are increased among bronchoalveolar lavage-recoverable cells. Similarly, intranasal immunization with recombinant antigen 85A with adjuvant induces CXCR6 expression on lung CD4 cells in BALB/c and C57BL/6 mice, while a synthetic ESAT6(1-20) peptide with adjuvant induces CXCR6 expression in C57BL/6 mice. Parenteral immunization fails to do so. Upregulation of CXCR6 is accompanied by a transient elevation of serum CXCL16 after intranasal immunization, and lung cells cultured ex vivo from mice immunized intranasally show increased production of CXCL16. Administration of CXCL16 and cognate antigen intranasally to mice previously immunized parenterally increases the number of antigen-specific T lymphocytes in the bronchoalveolar lavage-recoverable population, which mediates inhibition of the early growth of Mycobacterium tuberculosis after challenge. We conclude that expression of CXCR6 on lung T lymphocytes is a correlate of local protective immunity against Mycobacterium tuberculosis after intranasal immunization and that CXCR6 and CXCL16 play an important role in the localization of T cells within lung tissue and the bronchoalveolar lavage-recoverable compartment.

Indexed as

AcyltransferasesAdenoviridaeAdministration, IntranasalAnimalsAntigens, BacterialBiomarkersBronchoalveolar Lavage FluidCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesFemaleLungMiceMice, Inbred BALB CMice, Inbred C57BLMycobacterium tuberculosisReceptors, CXCRAcyltransferasesantigen 85A, Mycobacterium tuberculosisAntigens, BacterialBiomarkersCxcr6 protein, mouseReceptors, CXCRReceptors, CXCR6Tuberculosis VaccinesVaccines, Synthetic

Identifiers

PMID21628524
PMCPMC3147559
OpenAlexW2171522475

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.